47
Participants
Start Date
September 17, 2014
Primary Completion Date
December 13, 2017
Study Completion Date
December 13, 2017
Ceritinib
Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally,once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days. There were no breaks between dosing cycles.
Andrew and Patel Associates, Camp Hill
Holy Cross Hospital Holy Cross (2), Silver Spring
Wake Forest Baptist Health Health Sciences, Winston-Salem
Duke University Medical Center Seeley G. Mudd Bldg., Durham
Florida Cancer Specialists Florida Cancer Specialists (31, Fort Myers
Columbus Hematology and Oncology PA Columbus Hem and Onc (2), Columbus
Physicians Clinic of Iowa, Cedar Rapids
Aurora Research Institute, Milwaukee
Sanford University of South Dakota Medical Center Sanford Clinical Research, Sioux Falls
Sanford Hematology Oncology, Fargo
Northwestern University Northwestern (6), Chicago
Southeast Nebraska Oncology, Lincoln
Oncology Consultants Oncology Group, Houston
MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3), Houston
Sarah Cannon Research Institute, Denver
Utah Cancer Specialists Utah Cancer Specialists, Salt Lake City
Comprehensive Cancer Centers of Nevada CCC of Nevada (1), Las Vegas
St Joseph Heritage Healthcare St. Joseph Heritage, Santa Rosa
Swedish Cancer Institute Swedish Cancer Institute, Seattle
Rocky Mountain Cancer Centers Dept of Rocky Mountain (2), Greenwood Village
Rhode Island Hospital Rhode Island Hosp. (2), Providence
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY